The Pharmaceutical Market: Bahrain

The Pharmaceutical Market: Bahrain

Pharmaceuticals & Healthcare Report We expect Bahrain's pharmaceutical market values to grow steadily over the coming years. Key drivers will be volume-based, as the growing population increasingly requires more sophisticated treatments for lifestyle diseases and as healthcare provision expands and modernises . However, w hile some investment has been made into the local pharmaceutical manufacturing industry, imports will continue to supply the bulk of the demand. Headline Expenditure Projections Pharmaceuticals: BHD90mn (US$240mn) in 2011 to BHD100mn (US$260mn) in 2012; +6.12% in both local currency and US dollar terms. Forecastunchanged from Q412. Healthcare: BHD420mn (US$1.1bn) in 2011 to BHD500mn (US$1.2bn); +7.3% in both local currency and US dollar terms. Forecastunchanged from Q412. Medical devices: BHD30mn (US$70mn) in 2011 to BHD30mn (US$70mn) in 2012; +11.3% in both local currency and US dollar terms. Forecastunchanged from Q412. Risk/Reward Rating In our Q113 version of our Pharmaceutical Risk/Reward Ratings (RRRs) matrix for the Middle East and Africa (MEA), Bahrain is still ranked seventh out of the 30 markets surveyed in the region. The country's composite score is unchanged, at 54.9 out of the maximum 100. The country's position is propped up by its favourable risks profile, as its longer term rewards potential remains weighted down by its small population numbers. Globally, Bahrain ranks 38th out of the 95 markets assessed in total using our RRR model. Competitive Landscape The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. table Of Contents

executive Summary 5

swot Analysis 7

bahrain Pharmaceuticals And Healthcare Industry Swot Analysis 7

bahrain Political Swot Analysis 8

bahrain Economic Swot Analysis 8

bahrain Business...